浙江东亚药业股份有限公司关于股权激励部分限制性股票回购注销实施公告

Core Viewpoint - Zhejiang Dongya Pharmaceutical Co., Ltd. plans to repurchase and cancel 14,000 restricted stocks due to the departure of one incentive object from the 2024 Restricted Stock Incentive Plan [2][4][10] Summary by Sections Repurchase and Cancellation Reasons - The repurchase and cancellation of restricted stocks is based on the "Management Measures for Equity Incentives of Listed Companies" and the company's 2024 Restricted Stock Incentive Plan, as one incentive object has left the company [2][4] Details of the Repurchase and Cancellation - The decision for the repurchase was approved in meetings held on February 12, 2025, and the company has completed the necessary creditor notification procedures [3][4] - The repurchase involves one incentive object and a total of 14,000 restricted stocks, leaving 2,156,103 restricted stocks remaining after the cancellation [6][10] Repurchase Arrangement - The company has opened a dedicated securities account for the repurchase and expects to complete the cancellation by April 14, 2025 [6][10] Impact on Share Structure - After the cancellation, the company's share structure will be adjusted, but the specific changes will be confirmed by the China Securities Depository and Clearing Corporation [6][10] Legal Compliance and Commitments - The board of directors confirms that the decision-making process and information disclosure comply with relevant laws and regulations, ensuring no harm to the rights of the incentive objects or creditors [7][10] Convertible Bond Information - The repurchase of restricted stocks does not affect the conversion price of the company's convertible bonds, which remains at 20.28 yuan per share [10][16] - The company issued 6.9 million convertible bonds in 2023, with a total amount of 69 million yuan, and the bonds are currently trading on the Shanghai Stock Exchange [10][11]